AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

* RINVOQ(®) is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) * Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score ≤ 20) and improvements in eyebrows and eyelashes at week 24(1) * RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24 NORTH CHICAGO, Ill., July 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ(®) (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata (AA).(1)